Pain Therapeutics (PTIE) Getting Somewhat Favorable Press Coverage, Study Shows

Headlines about Pain Therapeutics (NASDAQ:PTIE) have been trending somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pain Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.821831820028 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Pain Therapeutics (PTIE) traded down $0.07 on Friday, reaching $6.28. The company had a trading volume of 29,568 shares, compared to its average volume of 86,646. Pain Therapeutics has a 52 week low of $3.10 and a 52 week high of $12.80. The stock has a market cap of $41.42, a price-to-earnings ratio of -3.43 and a beta of 2.83.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter. sell-side analysts expect that Pain Therapeutics will post -1.65 EPS for the current fiscal year.

Several equities research analysts recently weighed in on PTIE shares. Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th. ValuEngine lowered Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY NOTICE: “Pain Therapeutics (PTIE) Getting Somewhat Favorable Press Coverage, Study Shows” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply